M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

BioPharma Dive

Fulcrum s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.

Hematology

Read full story

pharminent June 2, 2026 (Last updated: June 3, 2026)

BioPharma Dive

Fulcrum s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.

Hematology

Read full story

Related Stories

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise